Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
158.55 USD | -0.21% | +4.56% | -10.25% |
12:21am | J&J says it has settled some talc claims, will continue bankruptcy strategy | RE |
Dec. 05 | Trending : Johnson & Johnson Sees Sales Growth for 2024 and Beyond | DJ |
Financials (USD)
Sales 2023 * | 85.4B | Sales 2024 * | 88.51B | Capitalization | 382B |
---|---|---|---|---|---|
Net income 2023 * | 18.65B | Net income 2024 * | 22.37B | EV / Sales 2023 * | 4,56x |
Net Debt 2023 * | 8.08B | Net cash position 2024 * | 2.87B | EV / Sales 2024 * | 4,28x |
P/E ratio 2023 * | 21,3x | P/E ratio 2024 * | 18,0x | Employees | 152,700 |
Yield 2023 * | 2,95% | Yield 2024 * | 3,07% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +0.37% | ||
1 week | +4.56% | ||
Current month | +2.52% | ||
1 month | +4.76% | ||
3 months | -1.33% | ||
6 months | +0.15% | ||
Current year | -10.25% |
1 week
151.92
160.02

1 month
145.64
160.02

Current year
144.95
180.93

1 year
144.95
181.04

3 years
144.95
186.69

5 years
109.16
186.69

10 years
81.79
186.69

Managers | Title | Age | Since |
---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 60 | 1988 |
Matthew Stuckley
DFI | Director of Finance/CFO | - | 2009 |
Joseph Wolk
DFI | Director of Finance/CFO | 56 | 1997 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 2019 |
D. Davis
BRD | Director/Board Member | 71 | 2014 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 2009 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.58% | 475 M€ | -4.07% | - | |
14.01% | 323 M€ | -7.50% | - | |
12.91% | 26 M€ | +10.47% | - | |
9.02% | 118 M€ | +10.27% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-05 | 158.55 | -0.21% | 7,268,151 |
23-12-04 | 158.88 | +0.32% | 8,920,279 |
23-12-01 | 158.38 | +2.41% | 10,342,901 |
23-11-30 | 154.66 | +1.68% | 12,481,867 |
23-11-29 | 152.11 | +0.32% | 5,190,026 |
Delayed Quote Nyse, December 05, 2023 at 04:00 pm EST
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-01-22
- Q4 2023 Earnings Call
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
158.55USD
Average target price
174.55USD
Spread / Average Target
+10.09%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.25% | 382 B $ | |
+60.77% | 529 B $ | |
+46.50% | 444 B $ | |
-4.25% | 269 B $ | |
-10.54% | 255 B $ | |
-13.61% | 231 B $ | |
+1.76% | 200 B $ | |
-9.57% | 198 B $ | |
-43.23% | 164 B $ | |
+3.13% | 145 B $ |